Quest Diagnostics price target lowered to $138 from $145 at Barclays

Barclays analyst Stephanie Davis lowered the firm’s price target on Quest Diagnostics to $138 from $145 and keeps an Equal Weight rating on the shares. The company’s Q4 print featured a headline beat offset by softer earnings guidance, the analyst tells investors in a research note. The firm says that while many of the earnings headwinds are known and one-timers, investors will be cautious on the more second half-weighted outlook and continue to view its long-term targets as a “show me” story.